Process Architecture in Biomanufacturing Facility Design

 
 
Wiley (Verlag)
  • 1. Auflage
  • |
  • erschienen am 3. November 2017
  • |
  • 384 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
978-1-119-36917-2 (ISBN)
 

Essential information for architects, designers, engineers, equipment suppliers, and other professionals who are working in or entering the biopharmaceutical manufacturing field

Biomanufacturing facilities that are designed and built today are radically different than in the past. The vital information and knowledge needed to design and construct these increasingly sophisticated biopharmaceutical manufacturing facilities is difficult to find in published literature-and it's rarely taught in architecture or design schools. This is the first book for architects and designers that fills this void. Process Architecture in Biomanufacturing Facility Design provides information on design principles of biopharmaceutical manufacturing facilities that support emerging innovative processes and technologies, use state-of-the-art equipment, are energy efficient and sustainable, and meet regulatory requirements.

Relying on their many years of hands-on design and operations experience, the authors emphasize concepts and practical approaches toward design, construction, and operation of biomanufacturing facilities, including product-process-facility relationships, closed systems and single use equipment, aseptic manufacturing considerations, design of biocontainment facility and process based laboratory, and sustainability considerations, as well as an outlook on the facility of the future.

  • Provides guidelines for meeting licensing and regulatory requirements for biomanufacturing facilities in the U.S.A and WHO-especially in emerging global markets in India, China, Latin America, and the Asia/Pacific regions
  • Focuses on innovative design and equipment, to speed construction and time to market, increase energy efficiency, and reduce footprint, construction and operational costs, as well as the financial risks associated with construction of a new facility prior to the approval of the manufactured products by regulatory agencies
  • Includes many diagrams that clarify the design approach

Process Architecture in Biomanufacturing Facility Design is an ideal text for professionals involved in the design of facilities for manufacturing of biopharmaceuticals and vaccines, biotechnology, and life-science industry, including architects and designers of industrial facilities, construction, equipment vendors, and mechanical engineers. It is also recommended for university instructors, advanced undergraduates, and graduate students in architecture, industrial engineering, mechanical engineering, industrial design, and industrial interior design.



Jeffery Odum, CPIP is the Managing Partner of the Strategic Manufacturing Concept Group, and a Global Technology Partner at NNE in the US Office located in Durham, North Carolina and a Teaching Fellow in the BTEC program at North Carolina State University.

Michael C. Flickinger, PhD is the Associate Director for Academic Programs at the Golden LEAF Biomanufacturing Training and Education Center (BTEC) and a Professor of Chemical and Biomolecular Engineering at North Carolina State University, Raleigh, North Carolina.

  • Englisch
  • Somerset
  • |
  • USA
  • 13,90 MB
978-1-119-36917-2 (9781119369172)
1119369177 (1119369177)
weitere Ausgaben werden ermittelt
  • "Title Page"
  • "Copyright"
  • "Table of Contents"
  • "Dedication"
  • "Contributors"
  • "Foreword"
  • "Preface: Why a Book on Process Architecture?"
  • "Chapter 1: Introduction to Biomanufacturing"
  • "1.1 Introduction"
  • "1.2 The Basic Constituents of Biopharmaceuticals"
  • "1.3 Enterprise Element #1â??Manufacturing Processes"
  • "1.4 Enterprise Element #2â??Manufacturing Facility"
  • "1.5 Enterprise Element #3â??Manufacturing Infrastructure"
  • "1.6 Controlling the Manufacturing Enterprise"
  • "1.7 Summary"
  • "References"
  • "Chapter 2: Productâ??Processâ??Facility Relationship"
  • "2.1 Introduction"
  • "2.2 The Characteristics of Biological Therapeutic Products"
  • "2.3 Understanding the Attributes"
  • "2.4 Factors that Impact Facility Design"
  • "References"
  • "Chapter 3: Regulatory Considerations of Biomanufacturing Facilities"
  • "3.1 Introduction"
  • "3.2 Regulatory â??Uncertainty,â?? A Two-Way Street"
  • "3.3 Design with the Patient in Mind: Assess the Patient, Product, Process, and Plant"
  • "3.4 Laws, Regulations, and Guidelines: Historical Background"
  • "3.5 Global Guidance Documents"
  • "3.6 Quality Systems and Risk Management"
  • "3.7 Product Changeover and Regulatory Assessment of Cleaning Validation"
  • "3.8 Control Strategy"
  • "3.9 Contract Manufacturing Organizations"
  • "3.10 FDA Inspections of Biopharm Facilities and Regulators' Priorities"
  • "3.11 Regulatory Meetings"
  • "3.12 Conclusion"
  • "References"
  • "Chapter 4: Biopharmaceutical Facility Design and Validation"
  • "4.1 Introduction"
  • "4.2 Designing for Compliance"
  • "4.3 Risk Management"
  • "4.4 Qualification/Verification"
  • "4.5 Process Validation"
  • "4.6 List of Abbreviations"
  • "References"
  • "Chapter 5: Closed Systems in Bioprocessing"
  • "5.1 Introduction"
  • "5.2 Definition of Closed Systems"
  • "5.3 Closed System Design"
  • "5.4 Impact on Facility Design"
  • "5.5 Impact on Operations"
  • "5.6 Summary"
  • "References"
  • "Chapter 6: Aseptic Manufacturing Considerations for Biomanufacturing Facility Design"
  • "6.1 Introduction"
  • "6.2 The Relationship to Biological Products"
  • "6.3 Process Attributesâ??Product Protection"
  • "6.4 Facility Design"
  • "6.5 Critical Area"
  • "References"
  • "Chapter 7: Facility Control of Microorganisms: Containment and Contamination"
  • "7.1 Introduction"
  • "7.2 Design Principles for Controlling Microorganisms"
  • "7.3 Controlling Viable Environmental Particulates"
  • "7.4 Reducing the Transport of Mold into the Bioprocess Facility"
  • "7.5 Reducing Mold Sources within the Bioprocess Facility"
  • "7.6 Biocontainment: An Overlay to Process Design"
  • "7.7 The Biocontainment Regulatory Environment"
  • "7.8 Principles of Biosafety"
  • "7.9 Principles of Biocontainment Facility Design"
  • "7.10 Design for the Entire Process"
  • "7.11 Conclusion"
  • "References"
  • "Further Reading"
  • "Chapter 8: Process-Based Laboratory Design"
  • "8.1 Introduction"
  • "8.2 Areas of Application/Scope"
  • "8.3 Translation of Process Elements into Laboratory Architecture"
  • "8.4 Key Steps in Planning Approach and Methodology"
  • "8.5 Laboratory Concept Development"
  • "8.6 SHE Considerations"
  • "8.7 Glossary"
  • "8.8 List of Abbreviations"
  • "References"
  • "Chapter 9: Case Study: Pharmaceutical Pilot Plant Design and Operation"
  • "9.1 Introduction"
  • "9.2 Operational Concepts and Processing Requirements"
  • "9.3 Design"
  • "9.4 Operation"
  • "References"
  • "Chapter 10: Addressing Sustainability in Biomanufacturing Facility Design"
  • "10.1 Introduction"
  • "10.2 Process Architecture"
  • "10.3 Water and Water Treatment"
  • "10.4 Energy Efficiency"
  • "10.5 Conclusion"
  • "Acknowledgments"
  • "References"
  • "Chapter 11: Technology's Impact on the Biomanufacturing Facility of the Future"
  • "11.1 Introduction"
  • "11.2 The Enabling Technologies"
  • "11.3 Elements of a Biomanufacturing Enterprise"
  • "11.4 Evolution of the Facility of the Future"
  • "11.5 The Futureâ??Summary and Conclusions"
  • "References"
  • "Glossary"
  • "Index"

Chapter 1
Introduction to Biomanufacturing


Mark F. Witcher

NNE, Durham, North Carolina, USA

1.1 Introduction


While the book covers designing biopharmaceutical and vaccine manufacturing facilities, this chapter is a brief introduction to biopharmaceutical manufacturing covering the essential elements of the overall biomanufacturing enterprise. Biomanufacturing is very complex and challenging. To be successful, the facility must be designed with a basic understanding of the overall manufacturing enterprise and how it functions. To simplify the discussion, vaccines will be combined with protein products for the purposes of this chapter.

The objective of this introduction is to:

  • Identify and describe a biopharmaceutical manufacturing enterprise's three basic elements (process, facility, and infrastructure);
  • Briefly describe the constituents used in biopharmaceutical manufacturing processes to appreciate the complexity and fundamental issues of operating the process's unit operations (UOs) within the facility;
  • Identify the basic process UOs typically used in biopharmaceutical manufacturing;
  • Provide a framework for describing, evaluating, and controlling the facility and process UOs, and;
  • Provide an understanding of how the overall manufacturing enterprise is operated and controlled.

In order to understand the challenges of biomanufacturing, we begin by looking at the overall manufacturing enterprise that surrounds and operates the manufacturing facility. As shown in Fig. 1.1, the manufacturing enterprise's myriad of components can be divided into three elements. The facility, process, and infrastructure are integrated and operated in concert to produce the product. As will be discussed, the three elements contain a wide variety of components required to achieve the overall objectives of the enterprise. Although the distribution used here provides structure to this introductory chapter, many variants or alternative distributions are possible.

Figure 1.1 The manufacturing enterprise is composed of three elements. Basically, the enterprise operates the process within the facility under the control of the infrastructure. The process and the facility are separate entities that can be run independently with the infrastructure providing the interface between the two. As shown in the side figure, the process is contained within the facility. The infrastructure element resides partially within the facility because the infrastructure is composed of both facility-specific and companywide, multifacility components.

In older enterprises, the facility and process are interdependent because the two were designed and constructed at the same time, usually for a specific product. In future enterprises, the process and facility will much less dependent on each other, with the multiproduct facility capable of running a wide variety of different processes. Because the process is not directly integrated with the facility, the processes can be moved in and out of a facility or moved to a different facility depending on manufacturing capacity or logistical requirements [1].

Manufacturing facilities are harder to run than they are to build. For the enterprise to be successful, the facility must be designed to be operated. All three elements must be carefully developed, so they can be integrated to assure the overall enterprise's success. They must work together in order to support and facilitate adequate control of all production activities to assure the efficient production of high quality product over the entire lifecycle of every product produced by the facility. This concept is emphasized by understanding that conformance lots or PPQ (process performance qualification) batches are more than just a test of the process [2]. Conformance lots are a test of the enterprise's ability to operate the process. Many conformance lot issues are encountered because the staff, part of the infrastructure, are not adequately trained and do not have the experience to execute the many tasks and activities required to successfully run the process and facility.

Starting from the beginning, the basic constituents of biopharmaceutical processes are cells, nucleic acids, and proteins.

1.2 The Basic Constituents of Biopharmaceuticals


Biopharmaceutical manufacturing uses relatively simple processes composed of UOs employing relatively simple pieces of equipment as compared to other industries, particularly those in the chemical and petrochemical industries. However, the constituents within the UOs are many orders of magnitude more complex. The purpose of this section is to provide a very brief introduction to the formidable challenges of managing and manipulating these constituents.

A defining element of biopharmaceuticals is the use of cells to produce the product. The product is most frequently a protein, but the product can be the cells themselves used for cellular therapies or in some cases the product can be genetic material manufactured in large quantities to modify or control genetic constructs and control mechanisms within the patient.

The cell is the largest and most complex element. The growth and characteristics of the cells are defined primarily by the genetic information stored in the cell's DNA. The machinery of the cells that use the genetic information is operated by proteins. The discussion will begin by describing the simplest element, proteins. Most pharmaceutical products are proteins manufacturing by the cell under the control of genetic constructs inserted into the cells using recombinant technology.

1.2.1 Proteins


Biopharmaceuticals are proteins. The product is created by cells in a complex environment of many complex biological molecules (carbohydrates, nucleic acids, lipids, and proteins) and cellular processes required for cell growth and product manufacturing. The discussion begins with an overview of proteins and their structure and behavior.

The fundamental structure of proteins is shown in Fig. 1.2. Proteins are polymers of 20 specific amino acids shown in Fig. 1.3 assembled by the cell according to the genetic code contained within the cell.

Figure 1.2 Proteins are a polymer of the 20 amino acids listed in Fig. 1.3. They are typically between 100 and 1500 amino acids in length. The term peptide refers to amino acid polymers of <25 amino acids.

Figure 1.3 While the Earth's natural environment contains hundreds of different amino acids, all life forms use only the 20 amino acids shown.

The sequence of amino acids forms the primary structure of the protein. Depending on many different structural and environmental factors, the amino acid chain is folded into higher order structures. These higher order structures can be defined as follows:

  • Primary: the linear amino acid sequence of the polypeptide;
  • Secondary: the localized folding of the primary structure into substructures sometimes called helices, strands, and sheets;
  • Tertiary: the combining of the secondary spiral and flat elements to form larger three-dimensional structures;
  • Quaternary: combining of tertiary structures to form a much larger complex three-dimensional structures.

The structures determine the protein's properties, including its safety and efficacy as a therapeutic product.

Additional protein complexity comes from post-translational modifications (PTMs) added to the protein during and after the four structural features described earlier are formed by the cell. PTMs change the behavior of the protein in solution and affect their therapeutic impact, safety, and efficacy in a wide variety of ways. The four structural features and PTMs along with the various altered product forms resulting from degradation, alternations, misincorporation, and aggregation combine with various impurities and contaminates from the manufacturing processes to determine the complex set of critical quality attributes (CQAs) that define the product's overall quality target product profile (QTPP) as defined in ICH Q8 (R2) [3]. The objective of the manufacturing process is to consistently produce a product described by the product's QTPP defined during development, tested in preclinical testing; and demonstrated to be safe and effective by clinical trials. For more details on the definition of biological products, ICH Q6B and ICH Q5E should be consulted [4, 5]. Biochemistry text books can be consulted for more information related to the structure, composition, and behavior of proteins [6-8].

All cells use thousands of proteins, called enzymes, to operate the machinery required to perform the myriad of internal maintenance functions, reproduce, and manufacture the product protein [9]. The production of proteins within the cell is carried out by complex metabolic pathways based on the genetic information contained within the cell. The genetic information is stored in the cell's DNA (deoxyribonucleic acid) formed by polymers of nucleic acids described later.

1.2.2 Nucleic Acids (DNA and RNA)


DNA provides a stable and efficient mechanism for storing and maintaining genetic information critical to the cell's ability to consistently and efficiently replicate without losing the ability to produce the target protein over many generations. DNA has a complex double helix spiral structure formed by two...

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

162,99 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung des WebShops erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok